Compare EYE & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYE | NUVB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | 305 |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2017 | 2020 |
| Metric | EYE | NUVB |
|---|---|---|
| Price | $18.65 | $4.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $28.18 | $13.00 |
| AVG Volume (30 Days) | 1.4M | ★ 5.0M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | 71.56 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,987,488,000.00 | $62,902,000.00 |
| Revenue This Year | $3.58 | $211.79 |
| Revenue Next Year | $5.10 | $45.15 |
| P/E Ratio | $34.81 | ★ N/A |
| Revenue Growth | 9.00 | ★ 698.96 |
| 52 Week Low | $14.75 | $3.92 |
| 52 Week High | $30.02 | $9.75 |
| Indicator | EYE | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 33.93 |
| Support Level | $16.02 | $4.10 |
| Resistance Level | $19.18 | $5.16 |
| Average True Range (ATR) | 0.61 | 0.24 |
| MACD | 0.25 | 0.03 |
| Stochastic Oscillator | 88.48 | 33.57 |
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.